The Biologics bet is landing early, with first orders in and revenue starting to trickle; the latest print cooled though, even as the valuation prices in the full ramp.
Overall read
5.2/10
Weak & rich
The three reads · this quarter
The Biologics bet is landing early, with first orders in and revenue starting to trickle; the latest print cooled though, even as the valuation prices in the full ramp.
Overall read
5.2/10
Weak & rich
The three reads · this quarter
The standing reads · change less often
Moat
No moat read published yet.
Key variables
5 tracked
lead: Customer retention rate (repeat business %)Retention remains high, indicating stable client relationships despite market challenges.
Walk the talk
Not enough data
as of Q1 FY270 of 0 guidance items delivered on time
Biologics CRADS operationalized with first order; meaningful revenue contribution expected from FY29.
Latest · newest first
1w ago · Business Update · severe
Company intimates a cyber security incident; impact not stated.
24 Jul 2026 · Business Update
Q1 earnings call transcript made available.
20 Jul 2026 · Business Update
Company announced unaudited financial results for Q1 FY 2026-27.
01 Jul 2026 · Fundraising
Allotted ESOPs under ESOP Plan 2021.
Where it sits